Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2020

01-12-2020 | Osteoporosis | Research article

Active ankylosing spondylitis increases blood loss during total hip arthroplasty for a stiff hip joint

Authors: Yong Hu, Wei-Zhou Jiang, Cheng-Long Pan, Tao Wang

Published in: BMC Musculoskeletal Disorders | Issue 1/2020

Login to get access

Abstract

Background

Total hip arthroplasty (THA) has been highlighted as the best treatment option for ankylosing spondylitis (AS) patients with advanced hip involvement. The huge blood loss associated with THA is a common concern of postoperative complications. Disease activity is a specific reflection of systematic inflammation of AS. The purpose of this study was to determine the effect of disease activity on blood loss during THA in patients with AS.

Methods

Forty-nine patients with AS who underwent unilateral THAs were retrospectively studied. Ankylosing Spondylitis Disease Activity Score (ASDAS) was employed to evaluate the disease activity. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) formula was used to assess the surgical blood loss. The patients were divided into active group (ASDAS≥1.3; n = 32) and stable groups (ASDAS< 1.3; n = 17) based on the ASDAS. Peri-operative laboratory values, plain radiographs, intra-operative data, transfusion volume, and use of hemostatic agents were recorded and statistically analyzed.

Results

The ASDAS, pre-operative C-reactive protein level, erythrocyte sedimentation rate, and fibrinogen concentration in the active group were higher than the stable group (all P < 0.05); however, the pre-operative hemoglobin concentration and albumin level were higher in the stable group (both P < 0.05). The total blood loss during THA in stable patients was 1415.31 mL and 2035.04 mL in active patients (P = 0.006). The difference between the two groups was shown to be consistent after excluding the gender difference (P = 0.030). A high transfusion rate existed in both groups (stable group, 76.47% with an average of 1.53 units; active group, 84.37% with an average of 2.31 units), but there was no significant difference between the two groups (both P > 0.05). Compensated blood loss, corresponding to transfusion, was noted significantly more in the active group compared to the stable group (P = 0.027). There was no significant difference with regard to functional recovery (P > 0.05).

Conclusion

Active AS patients are at high risk for increased blood loss during THA compared to stable patients. The underlying mechanism includes disorders of the coagulation and fibrinolytic systems, poor nutrition status, osteoporosis, imbalance of oxidative–antioxidative status and local inflammatory reaction. It is strongly recommended to perform THA in AS patients with stable disease.
Literature
1.
go back to reference Vander CB, Muñoz-Gomariz E, Font P, Mulero J, De VK, Boonen A, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology. 2010;49(1):73–81.CrossRef Vander CB, Muñoz-Gomariz E, Font P, Mulero J, De VK, Boonen A, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology. 2010;49(1):73–81.CrossRef
2.
go back to reference Wink F, Arends S, Maas F, Bootsma H, Griep EN, Bruyn GAW, et al. High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-alpha blocking therapy in ankylosing spondylitis. Rheumatology (Oxford, England). 2019;58(6):1040–6.CrossRef Wink F, Arends S, Maas F, Bootsma H, Griep EN, Bruyn GAW, et al. High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-alpha blocking therapy in ankylosing spondylitis. Rheumatology (Oxford, England). 2019;58(6):1040–6.CrossRef
3.
go back to reference Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/spondylitis Association of America/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of Ankylosing spondylitis and nonradiographic axial Spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282–98.PubMedCrossRef Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/spondylitis Association of America/Spondyloarthritis research and treatment network 2015 recommendations for the treatment of Ankylosing spondylitis and nonradiographic axial Spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282–98.PubMedCrossRef
4.
go back to reference Hawley S, Sacks S, Bowness P, Prieto-Alhambra D. Incidence of Total hip and knee replacement in UK patients with Ankylosing spondylitis. J Rheumatol. 2018;45(9):1334–6.PubMedCrossRef Hawley S, Sacks S, Bowness P, Prieto-Alhambra D. Incidence of Total hip and knee replacement in UK patients with Ankylosing spondylitis. J Rheumatol. 2018;45(9):1334–6.PubMedCrossRef
5.
go back to reference Jia L, Zhao J, He C, Tong W, Zou Y, Xu W. Comparison of blood loss after Total hip Arthroplasty between Ankylosing spondylitis and osteoarthritis. J Arthroplasty. 2016;31(7):1504–9.CrossRef Jia L, Zhao J, He C, Tong W, Zou Y, Xu W. Comparison of blood loss after Total hip Arthroplasty between Ankylosing spondylitis and osteoarthritis. J Arthroplasty. 2016;31(7):1504–9.CrossRef
6.
go back to reference Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010;113(2):482–95.PubMedCrossRef Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010;113(2):482–95.PubMedCrossRef
7.
go back to reference Guan M, Wang J, Zhao L, Xiao J, Li Z, Shi Z. Management of hip involvement in ankylosing spondylitis. Clin Rheumatol. 2013;32(8):1115–20.PubMedCrossRef Guan M, Wang J, Zhao L, Xiao J, Li Z, Shi Z. Management of hip involvement in ankylosing spondylitis. Clin Rheumatol. 2013;32(8):1115–20.PubMedCrossRef
8.
go back to reference Fraval A, Effeney P, Fiddelaers L, Smith B, Towell B, Tran P. OBTAIN A: outcome benefits of Tranexamic acid in hip Arthroplasty. A randomized double-blinded controlled trial. J Arthroplast. 2017;32(5):1516–9.CrossRef Fraval A, Effeney P, Fiddelaers L, Smith B, Towell B, Tran P. OBTAIN A: outcome benefits of Tranexamic acid in hip Arthroplasty. A randomized double-blinded controlled trial. J Arthroplast. 2017;32(5):1516–9.CrossRef
9.
go back to reference Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, et al. Oral and intravenous Tranexamic acid are equivalent at reducing blood loss following Total hip Arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2017;99(5):373–8.PubMedCrossRef Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, et al. Oral and intravenous Tranexamic acid are equivalent at reducing blood loss following Total hip Arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2017;99(5):373–8.PubMedCrossRef
10.
go back to reference Meermans G, Konan S, Das R, Volpin A, Haddad FS. The direct anterior approach in total hip arthroplasty: a systematic review of the literature. Bone Joint J. 2017;99-B(6):732–40.PubMedCrossRef Meermans G, Konan S, Das R, Volpin A, Haddad FS. The direct anterior approach in total hip arthroplasty: a systematic review of the literature. Bone Joint J. 2017;99-B(6):732–40.PubMedCrossRef
11.
go back to reference Aissaoui N, Rostom S, Hakkou J, Berrada Ghziouel K, Bahiri R, Abouqal R, et al. Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance. Rheumatol Int. 2012;32(7):2117–24.PubMedCrossRef Aissaoui N, Rostom S, Hakkou J, Berrada Ghziouel K, Bahiri R, Abouqal R, et al. Fatigue in patients with ankylosing spondylitis: prevalence and relationships with disease-specific variables, psychological status, and sleep disturbance. Rheumatol Int. 2012;32(7):2117–24.PubMedCrossRef
12.
go back to reference Sağ S, Nas K, Serdar Sağ M, Tekeoğlu I, Kamanli A. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis; 2018. p. 1–7. Sağ S, Nas K, Serdar Sağ M, Tekeoğlu I, Kamanli A. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis; 2018. p. 1–7.
13.
go back to reference Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–5.PubMedCrossRef Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–5.PubMedCrossRef
14.
go back to reference Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34(3):585–92.PubMedCrossRef Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004;34(3):585–92.PubMedCrossRef
15.
go back to reference So AK, Varisco PA, Kemkesmatthes B, Herkennemorard C, Chobazpéclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost. 2003;1(12):2510–5.PubMedCrossRef So AK, Varisco PA, Kemkesmatthes B, Herkennemorard C, Chobazpéclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost. 2003;1(12):2510–5.PubMedCrossRef
16.
go back to reference van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68(3):362–6.PubMedCrossRef van Eijk IC, Peters MJ, Serne EH, van der Horst-Bruinsma IE, Dijkmans BA, Smulders YM, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68(3):362–6.PubMedCrossRef
17.
go back to reference Arends S, Spoorenberg A, Brouwer E, van der Veer E. Clinical studies on bone-related outcome and the effect of TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2014;26(3):259–68.PubMedCrossRef Arends S, Spoorenberg A, Brouwer E, van der Veer E. Clinical studies on bone-related outcome and the effect of TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2014;26(3):259–68.PubMedCrossRef
18.
go back to reference Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):335–9.PubMedCrossRef Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):335–9.PubMedCrossRef
19.
go back to reference Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.PubMedPubMedCentralCrossRef Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.PubMedPubMedCentralCrossRef
20.
go back to reference George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee Arthroplasty. Arthritis Care Res (Hoboken). 2017;69(12):1845–54.CrossRef George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee Arthroplasty. Arthritis Care Res (Hoboken). 2017;69(12):1845–54.CrossRef
21.
go back to reference Singh M, Nagrath AR, Maini P. Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. JBJS. 1970;52(3):457–67.CrossRef Singh M, Nagrath AR, Maini P. Changes in trabecular pattern of the upper end of the femur as an index of osteoporosis. JBJS. 1970;52(3):457–67.CrossRef
22.
go back to reference Murphy M, Wallington T, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113(1):24.PubMedCrossRef Murphy M, Wallington T, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113(1):24.PubMedCrossRef
23.
go back to reference Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic surgery transfusion hemoglobin European overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):459–69.PubMedCrossRef Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, et al. Orthopedic surgery transfusion hemoglobin European overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003;43(4):459–69.PubMedCrossRef
24.
go back to reference Martinez V, Monsaingeonlion A, Cherif K, Judet T, Chauvin M, Fletcher D. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Hum Reprod. 1994;9(7):1297–9.CrossRef Martinez V, Monsaingeonlion A, Cherif K, Judet T, Chauvin M, Fletcher D. Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs. Hum Reprod. 1994;9(7):1297–9.CrossRef
25.
go back to reference Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811–8.PubMedCrossRef Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811–8.PubMedCrossRef
26.
go back to reference Zhao J, Li J, Zheng W, Liu D, Sun X, Xu W. Low body mass index and blood loss in primary Total hip Arthroplasty: results from 236 consecutive Ankylosing spondylitis patients. Biomed Res Int. 2014;2014(1):971–5. Zhao J, Li J, Zheng W, Liu D, Sun X, Xu W. Low body mass index and blood loss in primary Total hip Arthroplasty: results from 236 consecutive Ankylosing spondylitis patients. Biomed Res Int. 2014;2014(1):971–5.
27.
go back to reference Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth. 2005;95(1):33–42.PubMedCrossRef Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth. 2005;95(1):33–42.PubMedCrossRef
28.
go back to reference Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44(3):345–52.PubMedCrossRef Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44(3):345–52.PubMedCrossRef
29.
go back to reference Prati C, Racadot E, Cedoz JP, Wendling D. Thrombin generation in ankylosing spondylitis. Clin Rheumatol. 2011;30(4):511–4.PubMedCrossRef Prati C, Racadot E, Cedoz JP, Wendling D. Thrombin generation in ankylosing spondylitis. Clin Rheumatol. 2011;30(4):511–4.PubMedCrossRef
30.
go back to reference Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol. 2006;33(8):1516–22.PubMed Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol. 2006;33(8):1516–22.PubMed
31.
go back to reference Braun J. Van dHD, Doyle MK, Han C, Deodhar a, Inman R, et al. improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care Res. 2009;61(8):1032–6.CrossRef Braun J. Van dHD, Doyle MK, Han C, Deodhar a, Inman R, et al. improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Care Res. 2009;61(8):1032–6.CrossRef
32.
go back to reference Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211–5.PubMedCrossRef Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211–5.PubMedCrossRef
33.
go back to reference Heilig B, Pezzutto A, Lukoschek M, Hunstein W. Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis. Z Rheumatol. 1993;52(6):383–9.PubMed Heilig B, Pezzutto A, Lukoschek M, Hunstein W. Expression of TNF receptors in rheumatoid arthritis and ankylosing spondylitis. Z Rheumatol. 1993;52(6):383–9.PubMed
34.
go back to reference Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford, England). 2006;45(10):1288–93.CrossRef Martindale J, Smith J, Sutton CJ, Grennan D, Goodacre L, Goodacre JA. Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford, England). 2006;45(10):1288–93.CrossRef
35.
go back to reference Capaci K, Hepguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J. 2003;44(3):379–84.PubMedCrossRef Capaci K, Hepguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J. 2003;44(3):379–84.PubMedCrossRef
36.
go back to reference van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31(11):1529–35.PubMedPubMedCentralCrossRef van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31(11):1529–35.PubMedPubMedCentralCrossRef
37.
go back to reference El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26(10):2205–9.PubMed El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26(10):2205–9.PubMed
38.
go back to reference Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605–9.PubMedCrossRef Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605–9.PubMedCrossRef
39.
go back to reference Grazio S, Kusić Z, Cvijetić S, Grubišić F, Balenović A, Nemčić T, et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: A cross-sectional study; 2011. p. 2801–8. Grazio S, Kusić Z, Cvijetić S, Grubišić F, Balenović A, Nemčić T, et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: A cross-sectional study; 2011. p. 2801–8.
40.
go back to reference Wang DM, Zeng QY, Chen SB, Gong Y, Hou ZD, Xiao ZY. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clin Exp Rheumatol. 2015;33(4):465–70.PubMed Wang DM, Zeng QY, Chen SB, Gong Y, Hou ZD, Xiao ZY. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. Clin Exp Rheumatol. 2015;33(4):465–70.PubMed
41.
go back to reference Karakoc M, Altindag O, Keles H, Soran N, Selek S. Serum oxidative–antioxidative status in patients with ankylosing spondilitis. Rheumatol Int. 2007;27(12):1131–4.PubMedCrossRef Karakoc M, Altindag O, Keles H, Soran N, Selek S. Serum oxidative–antioxidative status in patients with ankylosing spondilitis. Rheumatol Int. 2007;27(12):1131–4.PubMedCrossRef
42.
go back to reference Azevedo VF, Faria-Neto JR, Stinghen A, Lorencetti PG, Miller WP, Gonçalves BP, et al. IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatol Int. 2013;33(7):1779–83.PubMedCrossRef Azevedo VF, Faria-Neto JR, Stinghen A, Lorencetti PG, Miller WP, Gonçalves BP, et al. IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents. Rheumatol Int. 2013;33(7):1779–83.PubMedCrossRef
43.
go back to reference Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Experimental Immunol. 2003;132(1):158–62.CrossRef Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Experimental Immunol. 2003;132(1):158–62.CrossRef
44.
go back to reference Braun J, Sieper J. Ankylosing spondylitis. Lancet (London, England). 2007;369(9570):1379–90.CrossRef Braun J, Sieper J. Ankylosing spondylitis. Lancet (London, England). 2007;369(9570):1379–90.CrossRef
45.
go back to reference Brown MA, Crane AM, Wordsworth BP. Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Curr Opin Rheumatol. 2002;14(4):354–60.PubMedCrossRef Brown MA, Crane AM, Wordsworth BP. Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Curr Opin Rheumatol. 2002;14(4):354–60.PubMedCrossRef
46.
go back to reference Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras M, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Library. 2015. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras M, Tanjong Ghogomu E, et al. TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Library. 2015.
Metadata
Title
Active ankylosing spondylitis increases blood loss during total hip arthroplasty for a stiff hip joint
Authors
Yong Hu
Wei-Zhou Jiang
Cheng-Long Pan
Tao Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2020
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-020-03278-2

Other articles of this Issue 1/2020

BMC Musculoskeletal Disorders 1/2020 Go to the issue